Skip to main content

Advertisement

ADVERTISEMENT

News

Michael Wang, MD
Conference Coverage
06/28/2024
At the 2024 ASCO Annual Meeting, Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
At the 2024 ASCO Annual Meeting, Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
At the 2024 ASCO Annual Meeting,...
06/28/2024
Oncology
FDA Approval
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
News
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology

Advertisement

News
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology

Advertisement

Eliza A Hawkes, MD
Conference Coverage
02/13/2024
Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.
Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.
Eliza A Hawkes, MD, shares...
02/13/2024
Oncology
News
01/24/2024
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
Yucai Wang, MD, PhD
Conference Coverage
01/10/2024
At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...
At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology

Advertisement

Bijal Shah, MD
Conference Coverage
01/08/2024
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology

Advertisement